Chemical formula: C₁₄H₂₂N₂O₃ Molecular mass: 266.341 g/mol PubChem compound: 21109
In patients with ischaemic heart disease, trimetazidine acts as a metabolic agent, preserving the myocardial high-energy phosphate intracellular levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C01EB15 | Trimetazidine | C Cardiovascular system → C01 Cardiac therapy → C01E Other cardiac preparations → C01EB Other cardiac preparations |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TRIMETAZIDINE Prolonged-release tablets | European Medicines Agency (EU) | MPI, EU: SmPC |
Trimetazidine is an active ingredient of these brands:
Albania (AL)
Austria (AT)
Brazil (BR)
Croatia (HR)
Cyprus (CY)
Ecuador (EC)
France (FR)
Hong Kong (HK)Ireland (IE)
Japan (JP)
Malta (MT)
Mexico (MX)
Poland (PL)
Singapore (SG)Spain (ES)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
